TherapeuticsMD, Inc. (NASDAQ: TXMD) submitted the New Drug Application (NDA) for TX-001HR, the company’s investigational bio-identical hormone therapy combination of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE